Tuo Xin Pharmaceutical Co., Ltd.

Announcement on the Temporary Suspension of the Shareholders' Meeting to Review Matters Related to the Issuance of A-Shares to Specific Objects

Announcement of Resolutions from the Twelfth Meeting of the Fifth Board of Directors

Announcement on the Termination of the Company's 2026 Annual Simplified Procedure for Issuing Shares to Specific Objects

Verification Report on the Use of Previously Raised Funds by Tuoxin Pharmaceutical Group Co., Ltd. as of December 31, 2025

Shareholder Dividend Return Plan for the Next Three Years (2026-2028)

Announcement on the Absence of Regulatory Measures or Penalties from Securities Regulatory Authorities and Stock Exchanges in the Past Five Years

Announcement on the Absence of Financial Assistance or Compensation Provided to Investors Participating in the Subscription of Shares Issued to Specific Objects

Announcement on the Dilution of Immediate Returns from Issuing A-Shares to Specific Objects in 2026 and Measures to Compensate and Commit Relevant Parties

Feasibility Analysis Report on the Use of Funds Raised from Issuing A-Shares to Specific Objects in 2026

Analysis Report on the Plan for Issuing A-Shares to Specific Objects in 2026

Plan for Issuing A-Shares to Specific Objects in 2026

Special Report on the Storage and Use of Previously Raised Funds

Announcement on the Disclosure of the Plan for Issuing A-Shares to Specific Objects in 2026

Announcement on the Approval Notification for the Supplementary Application of the Raw Material Drug Adenosine Monophosphate from Wholly-owned Subsidiary

Announcement of the resolution of the 11th meeting of the fifth board of directors

Q1 2026 report

Announcement on the absence of regulatory measures or penalties by securities regulatory authorities and stock exchanges in the past five years

Announcement on the revision of relevant documents regarding the proposal for the issuance of stocks to specific objects through simplified procedures for 2026

Verification report on the use of previously raised funds by Tuoxin Pharmaceutical Group Co., Ltd. as of March 31, 2026

Special report on the storage and use of previously raised funds

Analysis report on the proposal for the issuance of stocks to specific objects through simplified procedures for 2026 by Tuoxin Pharmaceutical Group Co., Ltd. (revised version)

Proposal for the issuance of stocks to specific objects through simplified procedures for 2026 by Tuoxin Pharmaceutical Group Co., Ltd. (revised version)

Announcement on the absence of financial assistance or compensation to investors participating in the subscription through direct or related parties in this issuance of stocks to specific objects through simplified procedures

Announcement on the dilution of immediate returns and measures to make up for it regarding the issuance of stocks to specific objects through simplified procedures for 2026 (revised version)

Announcement on the change of food production license of the subsidiary

Announcement on the Change of Company Directors

Announcement of Resolutions from the 2025 Annual Shareholders' Meeting

Legal Opinion Letter from Beijing Kangda Law Firm Regarding the 2025 Annual Shareholders' Meeting of Tuoxin Pharmaceutical Group Co., Ltd.

Reminder Announcement for the 2025 Annual Shareholders' Meeting

Announcement on Holding the 2025 Online Performance Presentation